MiR-103a-3p aggravates renal cell carcinoma by targeting
TMEM33.
Am J Transl Res 2021;
13:12694-12703. [PMID:
34956484 PMCID:
PMC8661195]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2021] [Accepted: 08/31/2021] [Indexed: 06/14/2023]
Abstract
OBJECTIVE
We investigated the mechanism of miR-103a-3p-mediated renal cell carcinoma (RCC) progression.
METHODS
The miR-103a-3p expressions were measured in clinical samples and in two RCC cell lines. MiR-103a-3p was inhibited or over-expressed in the 786-O and UO31 cell lines, respectively.
RESULTS
We found that miR-103a-3p is closely related to the development of RCC cells. A bioinformatics analysis and a dual-luciferase reporter gene assay revealed that there is a direct interaction between TMEM33 and miR-103a-3p. Moreover, a rescue assay further confirmed that TMEM33 overexpression can attenuate miR-103a-3p-induced RCC cell development.
CONCLUSION
miR-103a-3p exerts a carcinogenic function in RCC by regulating TMEM33, a finding that may provide new insights into the development of prognostic markers and therapeutic targets for RCC.
Collapse